# LIFECORE BIOMEDICAL, INC. (LFCR) · Edgar & Edgarette company card

> Lifecore Biomedical (LFCR) grew revenue 0.5% in FY2025 to $129 million, operating margin -13.4% against a -3.8% median for pharmaceutical preparations, equity 0.6% of assets. Every figure is from the company’s own annual report filed with the SEC.

SEC CIK 1005286 · fiscal year ended 2025-05-25 · 5 audited years read · [page](https://www.pops4.com/boards/company/LFCR) · [JSON](https://www.pops4.com/boards/company/LFCR.json)

## Figures, as filed in the 10-K

| Measure | Value |
|---|---|
| Revenue | $129M |
| Revenue growth, 1 year | 0.5% |
| Revenue growth per year | 6.3% |
| Operating margin | -13.4% (prior year -6.9%) |
| Net margin | -30.0% |
| Operating cash flow | −$206,000 |
| Capital spending | $13M |
| Free cash flow | −$14M |
| Cash | $8M |
| Long-term debt | $130M |
| Total assets | $239M |
| Total equity | $1M |
| Equity ÷ assets | 0.6% |
| Return on equity | -2898.0% |
| Dividend per share | — |
| Dividend years rising | — |

## Readings, computed from those figures

- Altman Z: -1.75 (distress zone)
- Piotroski F: 4 of 9 (middling)
- Health Harbor boat: Old boat · three warning signs · slow and jumpy: growing slower than its size class, with revenue that swings more; operating cash flow was negative; operating loss: a margin of -13.4% in FY2025
- Cash Compass: Fading · slow and jumpy, lagging its peers

## Edgarette's reading

Exposure: revenue $128.9M (FY2025), total debt $130.4M. Experience: revenue up 0.5% on the year, up 6.3% a year over 4 years; operating margin -13.4%, down from -6.9%. Soundness: equity 0.6% of assets, return on equity -2898.0%. Credibility: four or more audited years, reasonable weight. Range: 80% of past cases like this landed between $107.7M and $156.7M next year (method v4.1: its own 4-year record of growth weighed at 50% against $100M–1B filers; across 2019–2025, 69.0% landed inside, 83.4% on the one year the method never saw). In a shock year the stress range is $97.9M to $172.9M. A statistical range, not company guidance. Against peers (114 filers, $50M+ revenue, pharmaceutical preparations): operating margin -13.4% against a -3.8% median; growth 0.5% against 13.7%.

## Health Watch, last 12 months

- Item 5.02 Director or officer change: 2, latest 2026-06-05 ([filing](https://www.sec.gov/Archives/edgar/data/1005286/000100528626000023/0001005286-26-000023-index.htm))

## Recent filings

- 8-K · filed 2026-11-05 · 8.01 Other Events · [filing](https://www.sec.gov/Archives/edgar/data/1005286/000100528626000049/0001005286-26-000049-index.htm)
- 10-Q · filed 2026-11-04 · [filing](https://www.sec.gov/Archives/edgar/data/1005286/000100528626000046/0001005286-26-000046-index.htm)
- 8-K · filed 2026-11-04 · 2.02 Results of Operations and Financial Condition; 9.01 Financial Statements and Exhibits · [filing](https://www.sec.gov/Archives/edgar/data/1005286/000100528626000045/0001005286-26-000045-index.htm)
- 8-K · filed 2026-10-20 · 8.01 Other Events · [filing](https://www.sec.gov/Archives/edgar/data/1005286/000100528626000040/0001005286-26-000040-index.htm)
- 8-K · filed 2026-09-29 · 1.01 Entry into a Material Definitive Agreement; 9.01 Financial Statements and Exhibits · [filing](https://www.sec.gov/Archives/edgar/data/1005286/000100528626000036/0001005286-26-000036-index.htm)
- 8-K · filed 2026-09-28 · 1.01 Entry into a Material Definitive Agreement; 7.01 Regulation FD Disclosure; 9.01 Financial Statements and Exhibits · [filing](https://www.sec.gov/Archives/edgar/data/1005286/000114036126037767/0001140361-26-037767-index.htm)

## Sources

- facts: https://data.sec.gov/api/xbrl/companyfacts/CIK0001005286.json
- filings: https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=1005286

## Cite

POPS4, Edgar & Edgarette: LIFECORE BIOMEDICAL, INC. (LFCR) company card, from the company's own SEC filings, accessed 2026-11-14, https://www.pops4.com/boards/company/LFCR. CC BY 4.0. For a figure, add the filing URL under filings or sources.

DOI https://doi.org/10.5281/zenodo.23672509 · catalog https://www.pops4.com/boards/catalog.json · Figures as filed with the SEC. Card text CC BY 4.0, POPS4.

Reporting, not investment advice. No price targets and no trading recommendations.

Figures are as filed in audited 10-K reports and can move with restatements, acquisitions, disposals or a change in fiscal year. A range set from how past company-years turned out is not a promise about the next one, and says nothing about the share price.